Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research. A lack of knowledge about cellular pathways critical to the development of dementia, however, has stood in the way of significant clinical advance. But now, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) are breaking through that barrier. They show, for the first time in an animal model, that tau pathology – the second-most important lesion in the brain in patients with Alzheimer’s disease – can be reversed by a drug.
“We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,” explained senior investigator Domenico Praticò, MD, Scott Richards North Star Foundation Chair for Alzheimer’s Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer’s Center at Temple at LKSOM. The study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.
The researchers landed on their breakthrough after discovering that inflammatory molecules known as leukotrienes are deregulated in Alzheimer’s disease and related dementias. In experiments in animals, they found that the leukotriene pathway plays an especially important role in the later stages of disease.
“At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage,” Dr. Praticò said. “Having discovered this, we wanted to know whether blocking leukotrienes could reverse the damage, whether we could do something to fix memory and learning impairments in mice having already abundant tau pathology.”
To recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Praticò and colleagues used specially engineered tau transgenic mice, which develop tau pathology – characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability – as they age. When the animals were 12 months old, the equivalent of age 60 in humans, they were treated with zileuton, a drug that inhibits leukotriene formation by blocking the 5-lipoxygenase enzyme.
After 16 weeks of treatment, animals were administered maze tests to assess their working memory and their spatial learning memory. Compared with untreated animals, tau mice that had received zileuton performed significantly better on the tests. Their superior performance suggested a successful reversal of memory deficiency.
To determine why this happened, the researchers first analyzed leukotriene levels. They found that treated tau mice experienced a 90-percent reduction in leukotrienes compared with untreated mice. In addition, levels of phosphorylated and insoluble tau, the form of the protein that is known to directly damage synapses, were 50 percent lower in treated animals. Microscopic examination revealed vast differences in synaptic integrity between the groups of mice. Whereas untreated animals had severe synaptic deterioration, the synapses of treated tau animals were indistinguishable from those of ordinary mice without the disease.
“Inflammation was completely gone from tau mice treated with the drug,” Dr. Praticò said. “The therapy shut down inflammatory processes in the brain, allowing the tau damage to be reversed.”
The study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma. “Leukotrienes are in the lungs and the brain, but we now know that in addition to their functional role in asthma, they also have a functional role in dementia,” Dr. Praticò explained.
“This is an old drug for a new disease,” he added. “The research could soon be translated to the clinic, to human patients with Alzheimer’s disease.”
The Latest on: Dementia
via Google News
The Latest on: Dementia
- Qatar joins world to challenge stigma surrounding dementiaon September 7, 2019 at 4:38 am
Doha: Qatar has joined the world to raise awareness and challenge the stigma that surrounds dementia by participating in World Alzheimer's Month, the international campaign held each September.
- Scientists Study Whether Virtual Reality Can Prevent Cognitive Decline, Dementiaon September 7, 2019 at 12:40 am
LOS ANGELES - For three days a week, Wayne Garcia has been getting an unconventional workout. He starts by putting on a virtual reality (VR) headset. He then gets on a specially designed exercise bike ...
- Dementia dogs project saved by £50,000 fundraising driveon September 6, 2019 at 9:23 am
A project providing trained dogs to help dementia patients has been saved following a fundraising campaign. The Dementia Dogs Project assists people with the condition by pairing them with pets which ...
- This device could cut older people’s risk of dementia, depression and fallson September 6, 2019 at 4:54 am
Research suggests there’s a simple — but expensive — way to possibly cut the risk of Alzheimer’s, depression and injuries from falls. One small device can make a big difference in the lives of older ...
- LA County Celebrates Year Anniversary Of Program That Tracks People With Alzheimer’s, Dementiaon September 6, 2019 at 12:38 am
LOS ANGELES (CBSLA) — Many people who suffer from dementia, Alzheimer’s or autism can walk away and get lost. A program called “LA Found” is celebrating a one-year anniversary and by all ...
- Understanding Dementia, which increases with ageon September 5, 2019 at 9:19 pm
Over a six-month period, a 78-year-old businessman with a clever wit and superb leadership skills became less able to talk. He gradually became more confused and lost his ability to learn new things.
- Marriage may decrease risk of developing dementia, study sayson September 5, 2019 at 11:19 am
Marriage has been said to deflect depression, stave off stress, even help people live longer. Now a new study says it may also decrease your chance of developing dementia. Dementia is a general term ...
- Hearing aids lower dementia, depression risk for older adultson September 5, 2019 at 8:40 am
Sept. 5 (UPI) --After getting their first hearing aid, older adults have a lower likelihood of anxiety, depression and dementia compared to those who don't, a new study says. However, only about 12 ...
- Migraines a Risk Factor for Developing Dementia and Alzheimer's, Study Suggestson September 5, 2019 at 3:18 am
Migraines could raise the risk of developing dementia, including Alzheimer's disease, according to researchers. The study published in the International Journal of Geriatric Psychiatry involved 679 ...
via Bing News